165 related articles for article (PubMed ID: 38111589)
1. Circulating T follicular helper 2 cells, T follicular regulatory cells and regulatory B cells are effective biomarkers for predicting the response to house dust mite sublingual immunotherapy in patients with allergic respiratory diseases.
Shigehara K; Kamekura R; Ikegami I; Sakamoto H; Yanagi M; Kamiya S; Kodama K; Asai Y; Miyajima S; Nishikiori H; Uno E; Yamamoto K; Takano K; Chiba H; Ohnishi H; Ichimiya S
Front Immunol; 2023; 14():1284205. PubMed ID: 38111589
[TBL] [Abstract][Full Text] [Related]
2. Activated circulating T follicular helper cells and skewing of T follicular helper 2 cells are down-regulated by treatment including an inhaled corticosteroid in patients with allergic asthma.
Miyajima S; Shigehara K; Kamekura R; Takaki H; Yabe H; Ikegami I; Asai Y; Nishikiori H; Chiba H; Uno E; Takahashi H; Ichimiya S
Allergol Int; 2020 Jan; 69(1):66-77. PubMed ID: 31648923
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
4. Increase in the prevalence of follicular regulatory T cells correlates with clinical efficacy of sublingual immunotherapy with house dust mites.
Murao T; Kouzaki H; Arai H; Matsumoto K; Nakamura K; Kawakita K; Tojima I; Shimizu S; Yuta A; Shimizu T
Int Forum Allergy Rhinol; 2024 Jan; 14(1):57-67. PubMed ID: 37345377
[TBL] [Abstract][Full Text] [Related]
5. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
6. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis.
Hoshino M; Akitsu K; Kubota K; Ohtawa J
Allergol Int; 2022 Oct; 71(4):490-497. PubMed ID: 35718711
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of House Dust Mite Sublingual Immunotherapy Tablet in Allergic Asthma: A Systematic Review of Randomized Controlled Trials.
Wongsa C; Phinyo P; Sompornrattanaphan M; Krikeerati T; Lumkul L; Thongngarm T
J Allergy Clin Immunol Pract; 2022 May; 10(5):1342-1355.e24. PubMed ID: 35181547
[TBL] [Abstract][Full Text] [Related]
9. Association between biomarkers and house dust mite sublingual immunotherapy in allergic asthma.
Hoshino M; Akitsu K; Kubota K; Ohtawa J
Clin Exp Allergy; 2020 Sep; 50(9):1035-1043. PubMed ID: 32557974
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.
Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA
Front Immunol; 2021; 12():723814. PubMed ID: 34721385
[TBL] [Abstract][Full Text] [Related]
11. Serum Periostin as a Biomarker for Predicting Clinical Response to House Dust Mite Sublingual Immunotherapy in Allergic Rhinitis.
Hoshino M; Akitsu K; Kubota K; Ohtawa J
J Allergy Clin Immunol Pract; 2021 May; 9(5):1864-1870. PubMed ID: 33290915
[TBL] [Abstract][Full Text] [Related]
12. Dust mite component Analysis: Identifying key allergens components for effective immunotherapy in allergic rhinitis.
Huang J; Xiang R; Tan L; Deng Y; Tao Z; Zhang W; Xu Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111111. PubMed ID: 37925948
[TBL] [Abstract][Full Text] [Related]
13. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.
Potapova E; Bordas-Le Floch V; Schlederer T; Vrtala S; Huang HJ; Canonica GW; Valenta R; Matricardi PM; Mascarell L
Allergy; 2022 Oct; 77(10):3084-3095. PubMed ID: 35474582
[TBL] [Abstract][Full Text] [Related]
14. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
[TBL] [Abstract][Full Text] [Related]
15. Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy.
Sharif H; Acharya S; Dhondalay GKR; Varricchi G; Krasner-Macleod S; Laisuan W; Switzer A; Lenormand M; Kashe E; Parkin RV; Yi Y; Koc M; Fedina O; Vilà-Nadal G; Marone G; Eifan A; Scadding GW; Fear DJ; Nadeau KC; Durham SR; Shamji MH
J Allergy Clin Immunol; 2021 Feb; 147(2):663-676. PubMed ID: 33160969
[TBL] [Abstract][Full Text] [Related]
16. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis.
Meng Q; Liu X; Li P; He L; Xie J; Gao X; Wu X; Su F; Liang Y
Int Forum Allergy Rhinol; 2016 Aug; 6(8):862-70. PubMed ID: 27012942
[TBL] [Abstract][Full Text] [Related]
17. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
20. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.
O'Hehir RE; Gardner LM; de Leon MP; Hales BJ; Biondo M; Douglass JA; Rolland JM; Sandrini A
Am J Respir Crit Care Med; 2009 Nov; 180(10):936-47. PubMed ID: 19696440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
